Bristol-Myers Squibb (BMY) Announces Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Bristol-Myers Squibb (BMY) Announces Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus

Citi Reiterates $90 PT on Bristol-Myers Squibb Co. (BMY), 'We expect some FTC scrutiny...but given the Pfizer/ Arena outcome, we remain hopeful'

June 3, 2022 11:39 AM EDT

Citi analyst Andrew Baum reiterated a Buy rating and $90.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY)/

The analyst comments "PFEs ability to close the Arena deal with little FTC scrutiny, coupled with biotechs de-rating has unsurprisingly re-ignited M&A momentum with... More